ArticleACS omega2026
Apoptosis-Inducing Antitumor Activity of Curcumin-Loaded PCL Microfibers Incorporating Nano-Hydroxyapatite for Breast Cancer Therapy.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanohydroxyapatite composites' toxicity and biosafety for safe clinical translation.Nanoscale advances · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the most prevalent and life-threatening cancers worldwide, emphasizing the need for innovative therapeutic strategies that enable localized and sustained drug delivery. In this study, hybrid electrospun fibrous mats composed of poly-(ε-caprolactone) (PCL), nanohydroxyapatite (n-HAp), and curcumin (Cur) were successfully fabricated and evaluated for breast cancer treatment. The mats were produced by electrospinning with n-HAp concentrations of 1%, 3%, and 5% (w/w), and a fixed Cur content of 5% (w/w). Morphological analysis revealed uniform, randomly oriented, and bead-free fibers with average diameters of 2.34 ± 0.31 μm, 1.30 ± 0.90 μm, 1.10 ± 0.40 μm, and 1.50 ± 0.90 μm for PCL/Cur, PCL/1HAp-Cur, PCL/3HAp-Cur, and PCL/5HAp-Cur, respectively. FTIR and XRD analyses confirmed the successful incorporation of Cur and n-HAp into the PCL matrix without chemical degradation, while partial amorphization of the additives enhanced their dispersion within the fibers. Contact angle results indicated increased hydrophilicity with higher n-HAp content, reaching the lowest value (112 ± 1.8°) for PCL/3HAp-Cur. In vitro drug release experiments demonstrated a biphasic release behavior, with cumulative Cur release after 24 h of approximately 20%, 30%, 60%, and 80% for PCL/Cur, PCL/1HAp-Cur, PCL/3HAp-Cur, and PCL/5HAp-Cur, respectively. The release kinetics were best fitted to the Weibull model, indicating a diffusion-controlled mechanism. Biological evaluations revealed that PCL/3HAp-Cur exhibited the strongest anticancer activity, reducing MDA-MB-231 breast cancer cell viability to ∼45% after 48 h, while maintaining high biocompatibility with L929 fibroblast cells (>87% viability). Annexin V/PI flow cytometry confirmed apoptosis as the dominant mode of cell death. Overall, the findings demonstrate that PCL/3HAp-Cur nanofibrous mats offer an optimal balance of structural uniformity, sustained Cur release, enhanced hydrophilicity, and selective anticancer efficacy, making them promising candidates for localized breast cancer therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.